These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12088169)

  • 1. Surprising results in the study of paroxetine for generalized anxiety disorder.
    Ballas CA
    J Clin Psychiatry; 2002 Jun; 63(6):536; author reply 536-7. PubMed ID: 12088169
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales.
    Sugarman MA; Loree AM; Baltes BB; Grekin ER; Kirsch I
    PLoS One; 2014; 9(8):e106337. PubMed ID: 25162656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine treatment of mood and anxiety disorders in children and adolescents.
    Wagner KD
    Psychopharmacol Bull; 2003; 37 Suppl 1():167-75. PubMed ID: 14566209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mousetrap: managing the placebo effect in antidepressant trials.
    Lakoff A
    Mol Interv; 2002 Apr; 2(2):72-6. PubMed ID: 14993352
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
    Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
    Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substance-P antagonists: a new treatment for depression?
    Nutt D
    Lancet; 1998 Nov; 352(9141):1644-6. PubMed ID: 9853433
    [No Abstract]   [Full Text] [Related]  

  • 7. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
    Sheehan DV
    J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
    Sheehan DV
    J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing the treatment of mood and anxiety disorders: the first 10 years' experience with paroxetine.
    Nemeroff CB
    Psychopharmacol Bull; 2003; 37 Suppl 1():6-7. PubMed ID: 14566195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in recognition and treatment of social anxiety disorder: a 10-year retrospective.
    Stein MB
    Psychopharmacol Bull; 2003; 37 Suppl 1():97-107. PubMed ID: 14566205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo neuroimaging correlates of the efficacy of paroxetine in the treatment of mood and anxiety disorders.
    Kilts C
    Psychopharmacol Bull; 2003; 37 Suppl 1():19-28. PubMed ID: 14566198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder.
    Allgulander C; Cloninger CR; Przybeck TR; Brandt L
    Psychopharmacol Bull; 1998; 34(2):165-6. PubMed ID: 9640994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the effectiveness of crenotherapy in treating generalized anxiety disorder].
    Salamon R; Christine G; Olié JP; Dubois O
    Sante Publique; 2008; 20(2):105-12. PubMed ID: 18693409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo response in generalized anxiety: its effect on the outcome of clinical trials.
    Schweizer E; Rickels K
    J Clin Psychiatry; 1997; 58 Suppl 11():30-8. PubMed ID: 9363046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of controlled-release paroxetine.
    Golden RN
    Psychopharmacol Bull; 2003; 37 Suppl 1():176-86. PubMed ID: 14566210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group.
    Ravindran AV; Judge R; Hunter BN; Bray J; Morton NH
    J Clin Psychiatry; 1997 Mar; 58(3):112-8. PubMed ID: 9108813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of adepress (paroxetin) in generalized anxiety disorder].
    Chakhava VO; Budtueva FS; Borukaev RR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(8):25-9. PubMed ID: 20823826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
    Gibiino S; Mori E; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2013 Aug; 33(4):565-9. PubMed ID: 23764690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.